Monitor vote outcome; management is expected to prevail given low dissident ownership (~0.7%). If dissidents gain any seats, watch for operational disruption. Post-meeting, focus on BARDA Phase 2b COVID trial progress and cash runway into Q2 2027.
Price Chart
Executive Summary
Vaxart filed definitive additional proxy materials urging shareholders to vote FOR its six director nominees at the July 16, 2026 annual meeting, opposing a dissident group led by Daniel P. Houle that nominated three candidates. Management emphasizes the dissidents' lack of biotech experience and highlights CEO Steve Lo's role in securing BARDA funding and partnerships. The outcome likely favors the board given the dissidents' ~0.7% stake.
Key Facts
- Annual meeting scheduled for July 16, 2026.
- Board recommends voting FOR all six management nominees, WITHHOLD on dissident slate.
- Dissident stockholder Daniel P. Houle nominated three candidates with no biotech board experience.
- CEO Steve Lo negotiated BARDA award up to $453M and a $25M share purchase agreement.
- Average director tenure is 2.3 years; board recently refreshed.
Financial Impact
No new financial figures disclosed; BARDA award valued up to $453 million and $25 million share purchase agreement referenced as prior achievements.
Risk Factors
- Dissident slate could win seats if retail vote is swayed, potentially disrupting clinical and partnership momentum.
- Proxy contest may distract management from advancing key milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-063170 |
| Document: 0001213900-26-063170-index-headers.html | 0001213900-26-063170 |
| Document: 0001213900-26-063170-index.html | 0001213900-26-063170 |
| Document: 0001213900-26-063170.txt | 0001213900-26-063170 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 28, 2026 9w ago | 8-K | $0.4800 $0.5000 | ▲ +4.17% | ▲ +0.79% | $0.4301 (−10.40%) |
Jul 7, 2026 12w ago | 8-K | $0.5500 $0.6000 | ▲ +9.09% | ▲ +5.93% | $0.4301 (−21.80%) |
Jul 6, 2026 12w ago | DEFA14A | $0.6200 $0.5900 | ▼ −4.84% | ▼ −5.69% | $0.4301 (−30.63%) |
Jul 2, 2026 13w ago | DEFA14A | $0.6400 $0.5490 | ▼ −14.22% | ▼ −14.52% | $0.4301 (−32.80%) |
Jul 2, 2026 13w ago | 8-K | $0.6400 $0.5200 | ▼ −18.75% | ▼ −18.34% | $0.4301 (−32.80%) |
Jun 26, 2026 13w ago | DEFA14A | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4301 (−24.54%) |
Jun 26, 2026 13w ago | DEFA14A | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4301 (−24.54%) |
Jun 26, 2026 13w ago | 8-K | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4301 (−24.54%) |
Jun 16, 2026 15w ago | DEFA14A | $0.5600 $0.5300 | ▼ −5.36% | ▼ −6.21% | $0.4301 (−23.20%) |
Jun 8, 2026 16w ago | DEFA14A | $0.5800 $0.5502 | ▼ −5.14% | ▼ −6.53% | $0.4301 (−25.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access